Erectile DysfunctionPERFORMNCT07356609
Primary Care ERectile Function Outcome Registry for Men
An observational study of Erectile Dysfunction, run by Nabiqasim Industries (Pvt) Ltd.
Trial summary
The PERFORM registry is a structured, real-world data platform designed to systematically capture patient characteristics, disease severity and treatment patterns of Erectile Dysfunction (ED) across Pakistan. Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Erectile Dysfunction
- How many people
- 255 participants
- Where
- No sites listed yet
- Study dates
- 6 Feb 2026to 31 May 2027
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Study population: Adult Male ED patients
Who may be able to join
- Adult male above 18 years of age
- Married
- Diabetic
- Patient reports erectile dysfunction (symptomatic).
- Patient is eligible to be prescribed sildenafil by treating clinician.
Who cannot join
- If at any other PDE-5 inhibitor (sildenafil, tadalafil, vardenafil, avanafil)
- Concurrent use of organic nitrates (any form: glyceryl trinitrate, isosorbide mononitrate/dinitrate) - absolute contraindication
- Recent or unstable cardiovascular disease
- Myocardial infarction or stroke in last 3 months
- Unstable angina
- Uncontrolled arrhythmia or heart failure NYHA III-IV
Show all 10Show fewer
- Resting hypotension (SBP < 90 mmHg) or uncontrolled hypertension (SBP > 180 mmHg) per treating clinician
- Known severe hepatic impairment or severe renal impairment on dialysis (if local clinician deems unsafe)
- Known hypersensitivity to sildenafil or excipients
- Concomitant use of potent CYP3A4 inhibitors (e.g., ritonavir) - unless clinician documents safe plan/dose adjustment
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The PERFORM registry is a structured, real-world data platform designed to systematically capture patient characteristics, disease severity and treatment patterns of Erectile Dysfunction (ED) across Pakistan. By reflecting routine clinical practice, an ED registry provides valuable insights into the disease epidemiology, unmet needs, and variations in care across populations. It supports evidence-based decision-making, helps identifying early predictors, and inform guideline development, health policy, and personalized management strategies in male sexual health.
- Conditions
- Erectile Dysfunction
- Keywords
- Erectile dysfunction, male reproductive health, male sexual health
- Medical subject headings
- Erectile Dysfunction
What is being measured
The primary outcome is the main question the study is designed to answer.
Descriptive data of frequency, severity of ED in Pakistan
Prevalence
Measured: Baseline
Descriptive data [age, income (derivative of socio-economic class), rural/urban population and occupation]
Demographics
Measured: baseline
Secondary outcomes (2)
Age of diabetes in ED patients
Duration of diabetes in ED patients
Measured: baseline
Duration of ED
Disease duration
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jan 2026
- Study start6 Feb 2026 (estimated)
- Primary completion5 Feb 2027 (estimated)
- Study completion31 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Erectile DysfunctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 255 participants (estimated)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- Nabiqasim Industries (Pvt) Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Pakistan Society of Internal Medicine
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07356609
- Sponsor's protocol ID
- NQ/AP/SLR/Reg-007
- Acronym
- PERFORM
- Status last verified
- Jan 2026
- First submitted
- 8 Jan 2026
- Last updated
- 21 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Local sensitive data due to privacy concerns
Study at a glance
From the registry record, last updated by the sponsor on 21 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Primary Care ERectile Function Outcome Registry for Men
- ClinicalTrials.gov ID
- NCT07356609
- Acronym / sponsor ID
- PERFORM / NQ/AP/SLR/Reg-007
- Conditions
- Erectile Dysfunction
- Keywords
- Erectile dysfunction, male reproductive health, male sexual health
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 255 participants (estimated)
- Lead sponsor
- Nabiqasim Industries (Pvt) LtdIndustry (pharma, biotech, devices)
- Collaborators
- Pakistan Society of Internal Medicine
- Study start
- 6 Feb 2026 (estimated)
- Primary completion
- 5 Feb 2027 (estimated)
- Study completion
- 31 May 2027 (estimated)
- First posted
- 21 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The PERFORM registry is a structured, real-world data platform designed to systematically capture patient characteristics, disease severity and treatment patterns of Erectile Dysfunction (ED) across Pakistan. By reflecting routine clinical practice, an ED registry provides valuable insights into the disease epidemiology, unmet needs, and variations in care across populations. It supports evidence-based decision-making, helps identifying early predictors, and inform guideline development, health policy, and personalized management strategies in male sexual health.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Target follow-up
- 12 Months
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult Male ED patients
Key inclusion criteria (5 listed)
- Adult male above 18 years of age
- Married
- Diabetic
- Patient reports erectile dysfunction (symptomatic).
- Patient is eligible to be prescribed sildenafil by treating clinician.
Key exclusion criteria (10 listed)
- If at any other PDE-5 inhibitor (sildenafil, tadalafil, vardenafil, avanafil)
- Concurrent use of organic nitrates (any form: glyceryl trinitrate, isosorbide mononitrate/dinitrate) - absolute contraindication
- Recent or unstable cardiovascular disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Descriptive data of frequency, severity of ED in Pakistan
Time frame: Baseline
Prevalence
Descriptive data [age, income (derivative of socio-economic class), rural/urban population and occupation]
Time frame: baseline
Demographics
2 secondary outcomes
Age of diabetes in ED patients
Time frame: baseline
Duration of ED
Time frame: baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jan 2026.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided. Local sensitive data due to privacy concerns
Related trials for Erectile Dysfunction
RecruitingPhase 2
Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy
Erectile Dysfunction Following Radical Prostatectomy, Prostate Cancer
Active, not recruiting
Treatment With Peripheral Nerve Stimulation of the Pudendal Nerve in Patients With Erectile Dysfunction
Erectile Dysfunction, Electric Stimulation
Active, not recruiting
Efficacy of Low-dose Percutaneous Electrical Stimulation in Patients With Erectile Dysfunction.
Pudendal Nerve Injury, Erectile Dysfunction
Recruiting
Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease
Peyronie Disease, Erectile Dysfunction
Recruiting
Embolosclerotherapy Versus Deep Dorsal Vein Revascularization in Venogenic Erectile Dysfunction
Erectile Dysfunction Due to Venous Disorder, Erectile Dysfunction (ED)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Erectile Dysfunction, run by Nabiqasim Industries (Pvt) Ltd.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hussain Abidi (+923322583236, hussain.baqar@nabiqasim.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Descriptive data of frequency, severity of ED in Pakistan (time frame: Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2026.